MA51060A - Formulations de compositions de vaccin contre le virus de la dengue - Google Patents

Formulations de compositions de vaccin contre le virus de la dengue

Info

Publication number
MA51060A
MA51060A MA051060A MA51060A MA51060A MA 51060 A MA51060 A MA 51060A MA 051060 A MA051060 A MA 051060A MA 51060 A MA51060 A MA 51060A MA 51060 A MA51060 A MA 51060A
Authority
MA
Morocco
Prior art keywords
vaccine composition
dengue virus
virus vaccine
composition formulations
formulations
Prior art date
Application number
MA051060A
Other languages
English (en)
Inventor
Akhilesh Bhambhani
Jeffrey Thomas Blue
Erin J Green-Trexler
Lynne Ann Isopi
Morrisa Jones
Sherrie-Ann P Martin
Heidi Joanne Pixley
Michael S Ryan
Justin Stanbro
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA51060A publication Critical patent/MA51060A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA051060A 2017-12-07 2018-12-03 Formulations de compositions de vaccin contre le virus de la dengue MA51060A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762595842P 2017-12-07 2017-12-07

Publications (1)

Publication Number Publication Date
MA51060A true MA51060A (fr) 2021-03-17

Family

ID=66750326

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051060A MA51060A (fr) 2017-12-07 2018-12-03 Formulations de compositions de vaccin contre le virus de la dengue

Country Status (23)

Country Link
US (3) US20200390877A1 (fr)
EP (1) EP3720487A1 (fr)
JP (1) JP7042341B2 (fr)
KR (1) KR102494651B1 (fr)
CN (2) CN117752780A (fr)
AU (1) AU2018381213B2 (fr)
BR (1) BR112020011205A8 (fr)
CA (1) CA3083772A1 (fr)
CL (1) CL2020001463A1 (fr)
CO (1) CO2020006836A2 (fr)
CR (1) CR20200242A (fr)
DO (1) DOP2020000098A (fr)
EA (1) EA202091398A1 (fr)
EC (1) ECSP20032084A (fr)
GE (1) GEP20237539B (fr)
IL (1) IL274897A (fr)
JO (1) JOP20200140A1 (fr)
MA (1) MA51060A (fr)
MX (1) MX2020005857A (fr)
NI (1) NI202000039A (fr)
PE (1) PE20210654A1 (fr)
SG (1) SG11202005251VA (fr)
WO (1) WO2019112921A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117752780A (zh) * 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂
WO2023069123A1 (fr) * 2021-10-20 2023-04-27 3M Innovative Properties Company Compositions contenant du phosphate et de l'arginine et leur administration pour la suppression de la virulence
WO2024073362A2 (fr) * 2022-09-29 2024-04-04 Board Of Regents, The University Of Texas System Procédés et compositions pour le transport, le stockage et l'administration d'acides nucléiques et d'autres molécules
WO2024086605A1 (fr) 2022-10-18 2024-04-25 Takeda Vaccines, Inc. Formulation de vaccin contre la dengue

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0604566T3 (da) 1991-09-19 2000-04-10 Us Health Kimærisk og/eller vækstbegrænsede flavivirus
FR2702660B1 (fr) * 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US6190859B1 (en) 1995-04-17 2001-02-20 The United States Of America As Represented By The Secretary Of The Army Method and kit for detection of dengue virus
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1402075B1 (fr) 2001-05-22 2012-11-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Mise au point de mutations utiles pour l'attenuation des virus de la dengue et des virus de la dengue chimeriques
CN1909922B (zh) * 2002-02-26 2013-08-21 阿尔特拉瓦克斯股份有限公司 新的黄病毒抗原
CA2480128A1 (fr) * 2002-03-26 2003-10-09 Immunex Corporation Procedes d'utilisation d'un ligand flt3 dans des protocoles d'immunisation
EP2338508B1 (fr) 2002-05-03 2018-02-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus de Dengue chimérique recombiné rDEN3/4delta 30(ME), rDEN2/4delta30(ME) ou rDEN1/4delta30(ME) contenant une déletion de 30 nucléotides (delta30) dans une part de la region non traduit 3' du génome du virus de Dengue type 4, la-dite déletion de 30 nucleotides correspondant à la structure du TL2 stem-loop.
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
JP2008526870A (ja) 2005-01-05 2008-07-24 フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン 送達ビヒクル、生体作用活性物質およびウイルスワクチン
NZ564375A (en) 2005-06-24 2010-02-26 Intervet Int Bv Inactivated chimeric flavivirus vaccines and related methods of use
US20090155351A1 (en) 2005-10-04 2009-06-18 Alk-Abello A/S Solid Vaccine Formulation
CN101296705A (zh) * 2005-10-04 2008-10-29 阿尔克-阿贝洛有限公司 固体疫苗制剂
US8337860B2 (en) 2006-08-15 2012-12-25 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Development of dengue virus vaccine components
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CA2720570C (fr) 2007-04-06 2022-10-04 Inviragen, Inc. Methodes et compositions pour des virus de la dengue vivants et attenues
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CA2738024A1 (fr) * 2008-09-24 2010-04-01 Medimmune, Llc Procedes de purification de virus
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
CA2754603A1 (fr) 2009-03-13 2010-09-16 Lentigen Corporation Vaccins a vecteurs retroviraux non integrants
GB201002419D0 (en) * 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
SG10201508700XA (en) 2010-10-29 2015-11-27 Merck Sharp & Dohme Recombinant subunit dengue virus vaccine
KR20140033171A (ko) 2011-05-26 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 비활성화된 뎅기 바이러스 백신
DK2811981T3 (da) * 2012-02-07 2019-06-11 Infectious Disease Res Inst Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9974850B2 (en) * 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
US9254332B2 (en) * 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
SG11201510266SA (en) 2013-06-21 2016-01-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
WO2015057541A1 (fr) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Procédé d'obtention de formulations de vaccin séchées thermostables
JP2016534070A (ja) 2013-10-25 2016-11-04 ロイコケア・アクチェンゲゼルシャフト 安定化ワクチンの製造のための新規方法
EP3085357B1 (fr) 2013-12-16 2019-02-13 Takeda Pharmaceutical Company Limited Microaiguille
AU2014373928C1 (en) * 2013-12-31 2020-12-17 Access To Advanced Health Institute Single vial vaccine formulations
WO2015130157A1 (fr) 2014-02-28 2015-09-03 Universiti Malaya Amélioration de la production du virus de la dengue
EP3236997B1 (fr) 2014-12-22 2024-05-29 Merck Sharp & Dohme LLC Compositions de vaccin contre le virus de la dengue et procédés pour les utiliser
EP3303571A4 (fr) * 2015-06-04 2018-10-17 The University of Hong Kong Virus vivant atténué et procédés de production et d'utilisation
US20180296663A1 (en) * 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
WO2017056101A1 (fr) * 2015-09-30 2017-04-06 Panacea Biotec Limited Vaccin vivant atténué recombinant et stable contre la dengue
WO2017109698A1 (fr) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Formulation immunogène
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
CN109069615A (zh) * 2016-04-13 2018-12-21 武田疫苗股份有限公司 在儿童和年轻人中针对登革热病毒接种疫苗的组合物和方法
TWI766876B (zh) 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
AU2017327009A1 (en) 2016-09-19 2019-04-04 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US11268071B2 (en) 2017-03-30 2022-03-08 Merck Sharp And Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
CA3079151A1 (fr) 2017-10-16 2019-04-25 Serum Institute Of India Private Limited Compositions stables de vaccin comprenant, entre autres, un flavivirus recombinant vivant attenue et procede pour sa preparation
CN117752780A (zh) * 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂

Also Published As

Publication number Publication date
AU2018381213A1 (en) 2020-06-11
US11883480B2 (en) 2024-01-30
SG11202005251VA (en) 2020-07-29
BR112020011205A8 (pt) 2023-02-07
EP3720487A1 (fr) 2020-10-14
KR20200096272A (ko) 2020-08-11
KR102494651B1 (ko) 2023-01-31
US20240131144A1 (en) 2024-04-25
WO2019112921A1 (fr) 2019-06-13
CA3083772A1 (fr) 2019-06-13
US20230061673A1 (en) 2023-03-02
AU2018381213B2 (en) 2022-03-17
US20200390877A1 (en) 2020-12-17
CL2020001463A1 (es) 2020-09-25
JOP20200140A1 (ar) 2022-10-30
CR20200242A (es) 2020-07-17
DOP2020000098A (es) 2020-08-31
CN117752780A (zh) 2024-03-26
IL274897A (en) 2020-07-30
CN111447947B (zh) 2024-01-12
CN111447947A (zh) 2020-07-24
JP7042341B2 (ja) 2022-03-25
BR112020011205A2 (pt) 2020-11-17
ECSP20032084A (es) 2020-08-31
NI202000039A (es) 2020-09-24
EA202091398A1 (ru) 2020-09-01
JP2021505588A (ja) 2021-02-18
PE20210654A1 (es) 2021-03-31
MX2020005857A (es) 2020-09-09
CO2020006836A2 (es) 2020-06-19
GEP20237539B (en) 2023-09-11

Similar Documents

Publication Publication Date Title
MA47787A (fr) Vaccin contre le virus respiratoire syncytial
HK1250136A1 (zh) 具有改善的穩定性和免疫原性之疫苗組合物
MA51060A (fr) Formulations de compositions de vaccin contre le virus de la dengue
MA42991A (fr) Stabilisation de compositions pharmaceutiques de camptothécine
ZA201707475B (en) Compositions comprising antibody-duocarmycin drug conjugates
MA45381A (fr) Formulation de vaccin contre le vih
DK3634468T3 (da) Fast sammensætning til oral indgivelse
SG11201701256RA (en) Vaccine compositions against dengue virus diseases
IL280332A (en) A preparation containing a flu vaccine
GB201801566D0 (en) Methods and compositions for nanormulsion vaccine formulations
MA49837A (fr) Compositions pharmaceutiques
DK3355933T3 (da) Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser
SG11201911930SA (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
EP3305328A4 (fr) Composition protectrice de vaccin non gélatineuse et vaccin contre la grippe vivant atténué
HK1243927A1 (zh) 含有茶皂醇衍生物作爲活性成分的組合物
DK3389633T3 (da) Farmaceutiske sammensætninger, der omfatter phenylaminopyrimidinderivat
GB2562241B (en) Vaccine compositions
SG11202009147UA (en) Vaccine compositions
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3236997A4 (fr) Compositions de vaccin contre le virus de la dengue et procédés pour les utiliser
EP3355916A4 (fr) Vaccin vivant atténué recombinant et stable contre la dengue
IL271603A (en) Immunogenic preparations
IL263126B (en) Physiologically balanced injectable formulations of posantofitant
SI3381457T1 (sl) Fiziološka aktivna sestava, ki vsebuje N-acetilglukozamin za zdravljenje bolečin v hrbtu
DK3638211T3 (da) Farmaceutiske sammensætninger med forsinket vedvarende frigivelse